Virometix
Virometix AG is a Swiss biotechnology company focused on discovering and developing fully synthetic vaccines for infectious diseases and cancer. They utilize a proprietary modular and fully synthetic nanoparticle technology platform to create safe, effective, and scalable vaccines. Their lead indication targets Streptococcus pneumoniae infections, addressing a high unmet medical need. The company's approach involves structure-based vaccines designed to elicit precise, robust, and sustained immune responses, with advantages over traditional vaccine methods including safety, simplicity, and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
Virometix
Patents
Products
V-212 (peptide-based serotype-independent pneumococcal vaccine candidate)
Peptide-epitope vaccine candidate based on conserved pneumococcal surface protein domains presented on synthetic virus-like particles; preclinical models demonstrated serotype-independent antibody recognition and protection in mouse sepsis models.
V-306 (epitope-specific nanoparticle RSV vaccine candidate)
Epitope-focused nanoparticle vaccine candidate targeting a neutralizing epitope on RSV F protein; evaluated in a Phase I randomized, placebo-controlled, dose-escalating study with reported safety and immunogenicity.
Coronaviruses prophylactic vaccine candidates
Epitope-focused nanoparticle candidates targeting conserved regions of coronavirus spike proteins and including protective T-cell epitopes from multiple viral proteins, intended for broad protection across coronaviruses.
Cancer vaccine candidates (SVLP-based therapeutic approaches)
Programmes applying multivalent synthetic nanoparticle delivery to cancer antigens intended to elicit cytotoxic T-cell responses for therapeutic vaccination.
V-212 (peptide-based serotype-independent pneumococcal vaccine candidate)
Peptide-epitope vaccine candidate based on conserved pneumococcal surface protein domains presented on synthetic virus-like particles; preclinical models demonstrated serotype-independent antibody recognition and protection in mouse sepsis models.
V-306 (epitope-specific nanoparticle RSV vaccine candidate)
Epitope-focused nanoparticle vaccine candidate targeting a neutralizing epitope on RSV F protein; evaluated in a Phase I randomized, placebo-controlled, dose-escalating study with reported safety and immunogenicity.
Coronaviruses prophylactic vaccine candidates
Epitope-focused nanoparticle candidates targeting conserved regions of coronavirus spike proteins and including protective T-cell epitopes from multiple viral proteins, intended for broad protection across coronaviruses.
Cancer vaccine candidates (SVLP-based therapeutic approaches)
Programmes applying multivalent synthetic nanoparticle delivery to cancer antigens intended to elicit cytotoxic T-cell responses for therapeutic vaccination.
Services
Co-development partnerships applying synthetic nanoparticle platform to vaccines and other applications; licensing of platform IP and collaborative R&D.
Collaborative work on formulation of biologics and peptides, drug delivery approaches and monoclonal antibody development using the nanoparticle platform.
Co-development partnerships applying synthetic nanoparticle platform to vaccines and other applications; licensing of platform IP and collaborative R&D.
Collaborative work on formulation of biologics and peptides, drug delivery approaches and monoclonal antibody development using the nanoparticle platform.
Expertise Areas
- Peptide-based vaccine development
- Structure-guided/epitope-focused vaccine design
- Nanoparticle (SVLP) vaccine delivery
- Preclinical infectious disease models and in vivo efficacy
Key Technologies
- Synthetic virus-like particles (self-assembling lipopeptide nanoparticles)
- Conformational epitope-mimetic peptides and glycopeptides
- Solid-phase peptide synthesis (SPPS)
- AI-driven antigen identification and in silico design
News & Updates
Presentations on SARS-CoV-2 vaccine candidates and pneumococcal vaccines.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.
Discussion of V-212, a peptide-based vaccine against Streptococcus pneumoniae.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.
Discussion on engineered synthetic virus-like particles for antigen delivery.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.
Presentations on SARS-CoV-2 vaccine candidates and pneumococcal vaccines.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.
Discussion of V-212, a peptide-based vaccine against Streptococcus pneumoniae.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.
Discussion on engineered synthetic virus-like particles for antigen delivery.
Presentation of V-212, a peptide-based vaccine candidate against Streptococcus pneumoniae.